Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Wells

Showing results (211-220 of 277) with videos related to

Pageof 28
Sort By:
Cancer Letters|May 4, 2010
Chk2*1100delC Acts in synergy with the Ron receptor tyrosine kinase to accelerate mammary tumorigenesis in miceSara E Meyer, Belinda E Peace, El Mustapha Bahassi, et al.
Plant Direct|November 30, 2022
An open source plant kinase chemogenomics setMaria Florencia Ercoli, Priscila Zonzini Ramos, Rashmi Jain, et al.
Scientific Reports|April 7, 2022
Publisher Correction: BIRC2-BIRC3 amplification: a potentially druggable feature of a subset of head and neck cancers in patients with Fanconi anemiaKhashayar Roohollahi, Yvonne de Jong, Govind Pai, et al.
European Journal of Medicinal Chemistry|April 18, 2024
Discovery and optimization of narrow spectrum inhibitors of Tousled like kinase 2 (TLK2) using quantitative structure activity relationshipsChristopher R M Asquith, Michael P East, Tuomo Laitinen, et al.
The EMBO Journal|August 20, 2019
E2F1 proteolysis via SCF-cyclin F underlies synthetic lethality between cyclin F loss and Chk1 inhibitionKamila Burdova, Hongbin Yang, Roberta Faedda, et al.
Biorxiv : the Preprint Server for Biology|January 18, 2024
Discovery and Optimization of Narrow Spectrum Inhibitors of Tousled Like Kinase 2 (TLK2) Using Quantitative Structure Activity RelationshipsChristopher R M Asquith, Michael P East, Tuomo Laitinen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 23, 2020
Differential transcriptome response to proton versus X-ray radiation reveals novel candidate targets for combinatorial PT therapy in lymphomaMathieu Sertorio, Ali Nowrouzi, Mahdi Akbarpour, et al.
Scientific Reports|January 8, 2022
BIRC2-BIRC3 amplification: a potentially druggable feature of a subset of head and neck cancers in patients with Fanconi anemiaKhashayar Roohollahi, Yvonne de Jong, Govind Pai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2015
Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck CancersAnne J Lombardi, Elizabeth E Hoskins, Grant D Foglesong, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 27, 2015
Oral human papillomavirus is common in individuals with Fanconi anemiaSharon L Sauter, Susanne I Wells, Xue Zhang, et al.
Pageof 28

Showing results (211-220 of 277) with videos related to

Sort By:
Pageof 28
Cancer Letters|May 4, 2010
Chk2*1100delC Acts in synergy with the Ron receptor tyrosine kinase to accelerate mammary tumorigenesis in miceSara E Meyer, Belinda E Peace, El Mustapha Bahassi, et al.
Plant Direct|November 30, 2022
An open source plant kinase chemogenomics setMaria Florencia Ercoli, Priscila Zonzini Ramos, Rashmi Jain, et al.
Scientific Reports|April 7, 2022
Publisher Correction: BIRC2-BIRC3 amplification: a potentially druggable feature of a subset of head and neck cancers in patients with Fanconi anemiaKhashayar Roohollahi, Yvonne de Jong, Govind Pai, et al.
European Journal of Medicinal Chemistry|April 18, 2024
Discovery and optimization of narrow spectrum inhibitors of Tousled like kinase 2 (TLK2) using quantitative structure activity relationshipsChristopher R M Asquith, Michael P East, Tuomo Laitinen, et al.
The EMBO Journal|August 20, 2019
E2F1 proteolysis via SCF-cyclin F underlies synthetic lethality between cyclin F loss and Chk1 inhibitionKamila Burdova, Hongbin Yang, Roberta Faedda, et al.
Biorxiv : the Preprint Server for Biology|January 18, 2024
Discovery and Optimization of Narrow Spectrum Inhibitors of Tousled Like Kinase 2 (TLK2) Using Quantitative Structure Activity RelationshipsChristopher R M Asquith, Michael P East, Tuomo Laitinen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 23, 2020
Differential transcriptome response to proton versus X-ray radiation reveals novel candidate targets for combinatorial PT therapy in lymphomaMathieu Sertorio, Ali Nowrouzi, Mahdi Akbarpour, et al.
Scientific Reports|January 8, 2022
BIRC2-BIRC3 amplification: a potentially druggable feature of a subset of head and neck cancers in patients with Fanconi anemiaKhashayar Roohollahi, Yvonne de Jong, Govind Pai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2015
Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck CancersAnne J Lombardi, Elizabeth E Hoskins, Grant D Foglesong, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 27, 2015
Oral human papillomavirus is common in individuals with Fanconi anemiaSharon L Sauter, Susanne I Wells, Xue Zhang, et al.
Pageof 28